Artivion, Inc. (NYSE:AORT - Get Free Report) insider John E. Davis sold 6,457 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $176,340.67. Following the completion of the sale, the insider now directly owns 160,631 shares of the company's stock, valued at approximately $4,386,832.61. This trade represents a 3.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Artivion Price Performance
Shares of AORT traded down $0.02 during trading hours on Friday, reaching $25.34. 568,539 shares of the company's stock traded hands, compared to its average volume of 404,014. Artivion, Inc. has a 12 month low of $18.38 and a 12 month high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.06 billion, a PE ratio of -1,267.00 and a beta of 1.75. The firm's 50 day simple moving average is $29.51 and its 200-day simple moving average is $27.82.
Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.
Hedge Funds Weigh In On Artivion
A number of hedge funds and other institutional investors have recently bought and sold shares of AORT. Creative Planning boosted its holdings in shares of Artivion by 182.1% in the 3rd quarter. Creative Planning now owns 28,635 shares of the company's stock worth $762,000 after purchasing an additional 18,486 shares in the last quarter. RiverPark Advisors LLC boosted its stake in shares of Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company's stock valued at $143,000 after purchasing an additional 3,246 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Artivion by 2,481,700.0% in the 3rd quarter. Quest Partners LLC now owns 24,818 shares of the company's stock valued at $661,000 after purchasing an additional 24,817 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Artivion by 6.6% in the 3rd quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock valued at $280,000 after purchasing an additional 653 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Artivion by 28.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,596 shares of the company's stock valued at $522,000 after purchasing an additional 4,295 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on AORT. Oppenheimer lifted their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Friday, November 8th. Needham & Company LLC reduced their target price on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. JMP Securities reaffirmed a "market outperform" rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Finally, Stifel Nicolaus reduced their target price on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion has an average rating of "Buy" and an average price target of $31.40.
Read Our Latest Analysis on AORT
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
